Home / Newsroom / Engineering Case: Blister Packaging Containment Systems for Live Attenuated Vaccines
Engineering Case: Blister Packaging Containment Systems for Live Attenuated Vaccines
10/07/2018
Project Overview: An Ireland-based pharmaceutical manufacturer initiated an engineering inquiry for a small-scale blister packaging system. The project involves the processing and packaging of soft effervescent tablets composed of lyophilized bulk biological agents and chemical excipients, utilizing protocols standard to Oral Solid Dosage (OSD) manufacturing.
1. Biosafety and Containment Requirements
The final solid dosage product is a live attenuated vaccine containing a minor zoonotic human pathogen. To mitigate occupational exposure risks, strict biological containment is mandatory throughout the primary packaging phase. The system must operate as a fully closed unit or a compartmentalized open/closed architecture, ensuring absolute isolation until the tablets are hermetically sealed within the blister cavities.
2. Proposed Dust and Aerosol Control Architectures
To achieve the required containment levels during the blistering process, two engineering configurations are currently under technical evaluation:
Configuration A (Negative Pressure Chamber): Integration of enclosed material feeding via passive/active split-valve interfaces, combined with a negative-pressure packaging zone. The outfeed mechanism may remain open strictly post-sealing.
Configuration B (Laminar Flow Enclosure): Installation of the compact blister machine within the safe working zone of a laminar downflow booth, encapsulating material addition, packaging operations, and subsequent wash-in-place (WIP) or manual wipe-down procedures.
Engineering Assessment: JORNEN’s technical department is currently evaluating the mechanical feasibility of integrating negative-pressure containment modules and active valve feeding interfaces into our compact blister packaging models to formulate a comprehensive technical proposal and lead-time estimation.